Opinion|Videos|November 5, 2024
Improving Access and Equity in VMS Treatment
Key Takeaways
- Enhancing education for patients and healthcare providers can improve recognition and management of vasomotor symptoms associated with menopause.
- Socioeconomic disparities significantly impact access to healthcare resources, influencing the management of vasomotor symptoms.
Panelists discuss how to improve treatment rates for vasomotor symptoms (VMS) by identifying actionable steps, examining the influence of socioeconomic status on health care access, and proposing initiatives to ensure equitable care for all women experiencing menopause.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- (FIFFICK) What steps can be taken to improve treatment rates of VMS associated with menopause?
- (SMITH) How does the intersection of socioeconomic status and access to health care resources influence the management of VMS?
- (PINKERTON) What initiatives could help bridge these gaps and ensure more equitable care for all women experiencing menopause?
Advertisement
Related to this article
Invivyd presented preclinical IDWeek 2026 data on VMS063, an investigational antibody that neutralized B3 and D8 measles variants in vitro.
In more than 250,000 adults with prediabetes and obesity, GLP-1 users had lower risks of type 2 diabetes, death, and cardiovascular events.
Sphingolipid profiles in plasma and breath condensate differed between IPF and f-HP and tracked with disease severity, CHEST 2026 data show.
The FDA granted accelerated approval to the first plasmid DNA-based immunotherapy for adults with recurrent respiratory papillomatosis (RRP).
In nearly 443,000 US adults, both low-frequency and heavy cannabis use were linked to higher odds of cardiovascular disease, led by stroke.
Clinicians separate idiopathic hypersomnia from depression-related sleepiness and interpret real-world and trial data for better outcomes.
Erythema-based criteria miss skin of color, urging ROSCO phenotyping to improve diagnostic equity in dermatology.
New abstracts show the oral PCSK9 inhibitor cut LDL-C by 57% to 63% across PREVENT risk groups, with reductions maintained in an extension study.
Advertisement
Advertisement
Trending on AJMC
1
As Employers Pull Back on GLP-1s, Andel and Novo Offer a Workaround
2
Enlicitide LDL-C Lowering Holds Across Risk Levels Up to 2 Years
3
FDA Approves First Plasmid DNA-Based Immunotherapy for Adults With RRP
4
Tegoprubart Eases Symptom Burden vs Tacrolimus After Kidney Transplant
5